News

Merck’s decision triggers an additional $9 million payment to SurModics from Merck. Merck’s decision to discontinue the collaboration was made following a strategic review of its business and

According to the company, the SmoothShapes system uses a proprietary technology called Photomology that features an unique mechanism of action combining dynamic laser and light energy with mechanical

Most recently, Mr Elgin has served as vice president of business development and COO for Novaflux Technologies. Mr Elgin has earned his bachelor of arts degree from Queens

Ranaz has issued three million units at $0.60 per unit. Each unit comprises one share and half a warrant, with each whole warrant entitling its holder to purchase

The founder and the current CEO, Mohan Uttarwar will remain with the company, serve on the board of directors, and take on the role of chief strategy officer.

Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China, effective March 31,

The trial has demonstrated a favorable safety profile with Vivecon in 55 subjects enrolled across nine cohorts. The Phase I trial was designed as a single ascending dose

The supplemental new drug application (sNDA) filing was based upon data from the pivotal registrational trial, which provided estimates of the probability of patients attaining blood pressure goals

The placement was anchored by a commitment of A$6.5 million by existing major shareholders Alta Partners, GBS Venture Partners and Merck Sante, a subsidiary of Merck KGaA. These